Results 31 to 40 of about 27,127 (159)
Haematologica, 2014 Examination of abdominal subcutaneous fat aspirates is a practical, sensitive and specific method for the diagnosis of systemic amyloidosis. Here we describe the development and implementation of a clinical assay using mass spectrometry-based proteomics ...
Julie A. Vrana +9 more
doaj +1 more source
Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis
Hemato, 2021 Non-native immunoglobulin light chain conformations, including aggregates, appear to cause light chain amyloidosis pathology. Despite significant progress in pharmacological eradication of the neoplastic plasma cells that secrete these light chains, in ...
Gareth J. Morgan +2 more
doaj +1 more source
Skeletal Myopathy as the Initial Manifestation of Light Chain Multiple Myeloma
European Journal of Case Reports in Internal Medicine, 2020 Monoclonal gammopathies due to plasma cell dyscrasias can cause various rare neuromuscular disorders. The peripheral nervous system is most commonly affected, while muscle diseases associated with monoclonal gammopathies are rare. Skeletal myopathy, as a
Mohamed Reda Belkhribchia +5 more
doaj +1 more source
American journal of hematology/oncology, 2020 In localized light chain amyloidosis (locAL), amyloidogenic light chains (aLC) are produced and deposited locally by a B‐cell clone. We present 293 patients with immunohistochemically confirmed locAL.
M. Basset +14 more
semanticscholar +1 more source
Supportive Care and Symptom Management for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
Frontiers in Oncology, 2022 Immunoglobulin light chain (AL) amyloidosis is a disorder of clonal plasma cells characterized by deposition of amyloid fibrils in a variety of tissues, leading to end-organ injury.
Christopher E. Jensen +5 more
semanticscholar +1 more source
Localized Lymph Node Light Chain Amyloidosis
Case Reports in Hematology, 2015 Immunoglobulin-derived light chain amyloidosis can occasionally be associated with localized disease. We present a patient with localized lymph node light chain amyloidosis without an underlying monoclonal protein or lymphoproliferative disorder and ...
Binod Dhakal +3 more
doaj +1 more source
Duodenal biopsy: an unexpected confirmatory test for a patient with al-amyloidosis
Sri Lanka Journal of Medicine, 2019 SSystemic AL- amyloidosis is a disorder of protein folding in which there is extra-cellular accumulation as β pleated fibrillar deposits of monoclonal immunoglobulin light chain fragments. AL- amyloidosis is a rare clinical entity.
S. Pirasath +4 more
doaj +1 more source
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2022 Aim. Systemic amyloidosis caused by the synthesis and deposition of immunoglobulin light chains (AL amyloidosis) is a relatively rare disease that involves heart, kidneys, peripheral nervous system, gastrointestinal tract, and has a large number of ...
L. S. Kholopov +4 more
doaj +1 more source
Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis [PDF]
, 2016 Amyloid light-chain (LC) amyloidosis (AL amyloidosis) is a rare and fatal disease for which there are no approved therapies. In patients with AL amyloidosis, LC aggregates progressively accumulate in organs, resulting in organ failure that is ...
Ando, Y +10 more
core +1 more source
Producing amyloid fibrils in vitro: A tool for studying AL amyloidosis
Biochemistry and Biophysics Reports, 2023 Amyloid light-chain (AL) amyloidosis is the second most common form of systemic amyloidosis which is characterized by a high level of mortality and no effective treatment to remove fibril deposition.
Daria V. Sizova +7 more
doaj +1 more source